Dan Stanton, Managing editor

January 9, 2019

2 Min Read
China’s biotech growth drives Pall center of excellence in Shanghai
Pall's bioprocess center of excellence opened in Shanghai last month

Pall has established a Center of Excellence in Shanghai, China to service a biotech sector it says is worth $500 million and set to grow by double-digits.

Bioprocessing vendor Pall has several centers of excellence (CoE) set up globally to showcase its biomanufacturing offerings and has now opened a center in Shanghai to service the Chinese market.

“The goal of the CoE is to facilitate training and adoption of the advanced manufacturing technologies that will improve the productivity and robustness of our customers’ supply chains and decrease the time it takes to bring life changing therapies to market,” Bing Li, group VP & China president of Pall Corporation told BioProcess Insider.


Pall’s bioprocess center of excellence opened in Shanghai last month

“By opening this state-of-the-art facility, we hope to unlock new opportunities for our biopharmaceutical customers based in China, and for any global customers looking to enter or expand their operations in the Asia Pacific region.”

According to Li, the Chinese biotech market is currently valued at around $500 million (€436 million) and will continue to grow by double digits over the next few years.

“We are committed to supporting the rapid development of the Chinese biopharma market and the investment on our COE is one part of that commitment. Between Pall’s industry leading end to end solutions and our continuous and gene therapy platforms Pall offers the ability to tailor development and manufacturing solutions to best fit the needs of the wide range of therapies being developed and manufactured in China.

“The combination of our industry leading platforms and our capabilities to provide training, regulatory support and process development services allows Pall to support to the fast pace of growth and change in China’s biopharma market.”

The site, financial details of which have not been divulged, will display and offer testing and training across a range of Pall’s biomanufacturing offerings, including single-use cell culture solutions, cell clarification using acoustic wave technology, chromatography using automated packing techniques, viral clearance, tangential flow filtration and mixer / container modules.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like